Industry leaders came together on a shared platform at the FDA’s Rare Disease Day 2026 to discuss the novelty of the regulatory pathways, swifter review programs, and patient-centric innovations that contribute to the rapid development of treatments for rare diseases. The primary focus was on diseases such as NF1 and pediatric cancers. The key takeaway…
